Medtronic (MDT) Evolut TAVR System Shows Strong Performance at Two Years in Low Risk Trial

Go back to Medtronic (MDT) Evolut TAVR System Shows Strong Performance at Two Years in Low Risk Trial

Medtronic Evolutâ„¢ TAVR System Shows Strong Performance at Two Years in Low Risk Trial

May 18, 2021 9:00 AM EDT

DUBLIN, May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. Presented virtually today as a late-breaking clinical trial at the EuroPCR 2021 e-Course, results showed the Evolut TAVR platform was non inferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years (4.3% for... More